CTOs on the Move

iCyt Mission Technology

www.i-cyt.com

 
iCyt Mission Technology is a Champaign, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.i-cyt.com
  • 2100 S Oak St
    Champaign, IL USA 61820
  • Phone: 217.328.9396

Executives

Name Title Contact Details

Similar Companies

OpenTrons

We make robots for biologists. Our mission is to provide the scientific community with a common platform to easily share protocols and reproduce each other`s results. Our robots automate experiments that would otherwise be done by hand, allowing our community to spend more time pursuing answers to some of the 21st century`s most important questions.

Practical Applications

Practical Applications is a Boston, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Timtec

Timtec is a Newark, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

University Technologies International

University Technologies International is a Calgary, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Allucent

Allucent is a global biopharmaceutical services company founded in 2022 through the merger of several specialized providers. The company focuses on supporting small and mid-sized biotech firms in developing innovative treatments for patients with unmet medical needs. With over 30 years of combined experience, Allucent offers a range of services including regulatory consulting, clinical operations management, biometrics, and clinical pharmacology, particularly emphasizing oncology. Headquartered in Cary, North Carolina, Allucent has a strong global presence with offices in North America, Europe, Central/Eastern Europe, and Asia/Middle East. The company has conducted more than 825 clinical trials across over 70 countries, showcasing its extensive operational expertise. Allucent is dedicated to helping clients navigate the complexities of drug development and regulatory approval, ultimately accelerating the delivery of breakthrough therapies to patients.